These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 4648393)

  • 21. Immunologic properties of methylcholanthrene-induced sarcomas of neonatally thymectomized mice.
    Nomoto K; Takeya K
    J Natl Cancer Inst; 1969 Mar; 42(3):445-53. PubMed ID: 5779635
    [No Abstract]   [Full Text] [Related]  

  • 22. Heterotransplantation of mouse tumors to immunologically paralyzed rats.
    Suciu-Foca N
    Cancer Res; 1969 Feb; 29(2):338-48. PubMed ID: 4885388
    [No Abstract]   [Full Text] [Related]  

  • 23. Concomitant immunity and specific depression of immunity by residual or reinjected syngeneic tumor tissue.
    Vaage J
    Cancer Res; 1971 Nov; 31(11):1655-62. PubMed ID: 5121668
    [No Abstract]   [Full Text] [Related]  

  • 24. Tumor-associated antigens in isoantigenic variants of a 3-methylcholanthrene-induced sarcoma.
    Oth D; Berebbi M; Meyer G
    J Natl Cancer Inst; 1975 Oct; 55(4):903-8. PubMed ID: 52721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Further studies on cross-immunity among syngeneic tumors in mice.
    Usubuchi I; Nishimura S; Kudo H; Ito I; Sobajima Y
    Tohoku J Exp Med; 1975 Aug; 116(4):373-77. PubMed ID: 1188921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific desensitization of resistance against a syngeneic methylcholanthrene-induced sarcoma in C3Hf mice.
    Vaage J
    Cancer Res; 1972 Feb; 32(2):193-9. PubMed ID: 5058179
    [No Abstract]   [Full Text] [Related]  

  • 27. Actinomycin-D-resistant in vitro mouse cell line derived from a methylcholanthrene-induced sarcoma: decrease of malignancy and antigenic characteristics.
    Belehradek J; Biedler JL; Thonier M; Barski G
    Int J Cancer; 1974 Dec; 14(6):779-88. PubMed ID: 4142788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour-related antigen specificities associated with 3-methylcholanthrene-treated rat embryo cells.
    Embleton MJ; Baldwin RW
    Int J Cancer; 1979 Jun; 23(6):840-5. PubMed ID: 89103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of different doses of cyclophosphamide on the immune response of mice with a methylcholanthrene-induced sarcoma].
    Gordienko SP; Bergol'ts VM
    Vopr Onkol; 1973; 19(11):54-60. PubMed ID: 4785975
    [No Abstract]   [Full Text] [Related]  

  • 30. [Antibodies against cells of methylcholanthrene sarcoma in the blood of intact mice].
    Fedorovskaia MI; Vetrova EP; Umanskii IuA
    Biull Eksp Biol Med; 1973 Jul; 76(7):78-80. PubMed ID: 4774443
    [No Abstract]   [Full Text] [Related]  

  • 31. A microassay for humoral cytotoxicity demonstrating sublethal effects of antibody.
    Cleveland PH; McKhann CF; Johnson K; Nelson S
    Int J Cancer; 1974 Sep; 14(3):417-26. PubMed ID: 4459274
    [No Abstract]   [Full Text] [Related]  

  • 32. Acquired immunological tolerance and carcinogenesis by the mammary tumor virus. I. Influence of neonatal infection with the mammary tumor virus on the growth of spontaneous mammary adenocarcinomas.
    Morton DL
    J Natl Cancer Inst; 1969 Feb; 42(2):311-20. PubMed ID: 4303883
    [No Abstract]   [Full Text] [Related]  

  • 33. Circulating tumor antigens versus immune serum factors in depressed concomitant immunity.
    Vaage J
    Cancer Res; 1974 Nov; 34(11):2979-83. PubMed ID: 4425091
    [No Abstract]   [Full Text] [Related]  

  • 34. Tumor-specific transplantation immunity after cryosurgery.
    Myers RS; Hammond WG; Ketcham AS
    J Surg Oncol; 1969; 1(3):241-6. PubMed ID: 5406367
    [No Abstract]   [Full Text] [Related]  

  • 35. Occurrence of shared nonviral tumor-associated transplantation-type antigens among C3H/He mammary carcinomas.
    Vaage J
    Cancer Res; 1984 May; 44(5):1876-9. PubMed ID: 6201265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-secific immunity to chemically induced tumors. Evidence for immunologic specificity and shared antigenicity in lymphocyte responses to soluble tumor antigens.
    Frbes JT; Nakaw Y; Smith RT
    J Exp Med; 1975 May; 141(5):1181-200. PubMed ID: 47896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of crossreacting tumor antigens in ascitic derivatives from murine methylcholanthrene-induced sarcomas.
    Law LW
    Int J Cancer; 1984 Apr; 33(4):547-51. PubMed ID: 6200449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concomitant immunity to syngeneic methylcholanthrene-induced tumours in mice. Occurrence and specificity of concomitant immunity.
    Kearney R; Nelson DS
    Aust J Exp Biol Med Sci; 1973 Dec; 51(6):723-35. PubMed ID: 4788454
    [No Abstract]   [Full Text] [Related]  

  • 39. Role of H-2 antigens in the host response to methylcholanthrene-induced tumors.
    Ahrlund-Richter L; Klein E; Merino F
    Immunogenetics; 1982 Jan; 15(1):53-62. PubMed ID: 6979509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of lymphocytes and serum of C3Hf-Bu mice during the growth of methylcholanthrene-induced tumor and its regression following local irradiation.
    Jurin M; Suit HD
    Cancer Res; 1974 Apr; 34(4):672-8. PubMed ID: 4814987
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.